PR is also out of his depth. In saying that, PR is more knowledgeable and experienced with repurposed treatments, Marco with generics. Marco has vastly more experience negotiating partnerships and licensing deals, albeit for generics.
PAR will rely heavily on consultants like most early stage biopharma companies do. IND and clinical trial execution is irrelevant right now since the entire program is underway. The pathway to NDA is clear, although you're right to say the board lacks specialised expertise in this domain, particularly for negotiating partnerships.
I am intrigued (like most) as to why Marco is standing down and the 3 months notice given as opposed to 6 months. Hopefully we will get more of an explanation soon.
- Forums
- ASX - By Stock
- PAR
- Ann: Paradigm CEO steps down & Appointment of MD
Ann: Paradigm CEO steps down & Appointment of MD, page-90
-
- There are more pages in this discussion • 124 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M |
Open | High | Low | Value | Volume |
26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 130186 | 24.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 11571 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 130186 | 0.245 |
8 | 120363 | 0.240 |
5 | 126753 | 0.235 |
5 | 146782 | 0.230 |
2 | 53000 | 0.225 |
Price($) | Vol. | No. |
---|---|---|
0.250 | 11571 | 1 |
0.260 | 15236 | 1 |
0.265 | 59987 | 2 |
0.270 | 10000 | 1 |
0.275 | 16347 | 3 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online